NEW YORK (GenomeWeb News) – German startup biotech firm Blackfield today announced a collaboration with AstraZeneca in support of one of the biopharmaceutical firm's oncology drug development programs.
Blackfield will apply its genomics technologies and computational biology capabilities to validate preclinical models in support of AstraZeneca's program it said. Further details of AstraZeneca's program were not revealed.
Blackfield said that today's deal is its fourth since starting up a year ago. It also has service agreements with Janssen Pharmaceuticals, a division of Johnson & Johnson; Merck KGaA; and Boehringer Ingelheim.
Financial and other terms of the deal with AstraZeneca were not disclosed.
Based in Cologne, Blackfield generates datasets of genomic changes in various types of cancer, then applies computation biology to support the development of methods to molecularly diagnose and treat cancer.